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INTRODUCTION
Despite advances in the provision of renal replacement therapy, there still remains a high morbidity and mortality rate in hemodialysis patients. Increasing evidence links poor nutritional status to the increased morbidity and mortality observed in the hemodialysis patient (1, 2) .
Nutritional assessment is important to identify the patient with or at risk for malnutrition. Low levels of serum albumin and cholesterol have been shown to be strong predictors of mortality in the dialysis population (2) . These biochemical markers reflect long term malnutrition and may not accurately reflect early signs of inadequate protein and energy intake (1, 3) . A low serum level of transthyretin (formerly known as prealbumin) has also been shown to be an independent predictor of morbidity (4) and mortality (4) (5) (6) in the hemodialysis patient. Transthyretin levels are an early indicator of adequate or inadequate nutritional intake (7) , an index for the provision of adequate nutritional support (7, 8) and a marker for visceral protein anabolism (8) . Since serum transthyretin has a half life of two days and responds rapidly to increased or decreased nutritional intake (7) , it has been proposed as a short term marker of nutritional adequacy in the hemodialysis patient.
The protein catabolic rate (PCR) is a common parameter used to evaluate recent nutritional intake in hemodialysis patients. PCR is derived through urea kinetic modeling from the urea generation rate and expressed as normalized PCR (nPCR) in relation to body weight. If the patient is in a steady state, PCR is a reflection of dietary protein intake, thereby serving as an early marker of inadequate protein intake (9) . In a recent study examining the relationship of serum levels of transthyretin with dietary protein intake in hemodialysis patients, a correlation was found between low transthyretin levels (<30 mg/dl) and lower protein catabolic rates (nPCR) <1.2/gm/kg (10) . This finding merits further investigation and additional research to validate the correlation between low transthyretin and low protein catabolic rate.
JUSTIFICATION
A very limited amount of information has been published regarding the use of serum transthyretin as an early marker of malnutrition in the hemodialysis population. Even less information is available regarding the correlation of PCR with serum transthyretin levels. If low serum levels of transthyretin correlate with inadequate dietary protein as evidenced by low protein catabolic rates, serum transthyretin would serve as an easily accessible early indicator for aggressive nutrition intervention. The routine drawing of serum transthyretin levels in hemodialysis patients for nutritional assessment purposes would be justified by the above findings.
PURPOSE OF RESEARCH
The purpose of this study was to confirm the use of serum transthyretin as a valid early marker of poor nutritional status in the hemodialysis patient and to validate the correlation of low serum transthyretin levels with established nutrition assessment parameters and lower protein catabolic rates.
HYPOTHESIS TESTED
Primary:
1. Serum transthyretin levels less than 30 mg/dl correlate with normalized protein catabolic rates less than 1.0 gm/kg body weight/day.
2.
Low serum transthyretin levels correlate with low predialysis blood urea nitrogen.
3. Transthyretin levels increase/decrease prior to changes in serum albumin levels and cholesterol levels.
Secondary:
1. Serum transthyretin levels less than 30 mg/dl are indicative of inadequate energy intake as evidenced by a decrease in dry weight and body mass index.
2. There is no difference in transthyretin levels based on age, race, length of time on dialysis, or diabetic status.
REVIEW OF THE LITERATURE
The relationship between malnutrition and increased morbidity and mortality has been well established in the hemodialysis population (1, 2) . The nutrition markers, cholesterol and serum albumin, have been shown to have a strong predictive value of outcome in hemodialysis patients (2, 11) . Goldwasser et a. found that single measurements of albumin and cholesterol are independent predictors of survival for at least two years in both recently diagnosed and longstanding dialysis patients and these markers remain predictive even in patients receiving adequate dialysis (12) . These biochemical markers reflect long term malnutrition and may not accurately identify the early signs of inadequate protein and energy intake (1, 3) . A valid short term indicator of malnutrition is needed for early identification of the hemodialysis patient at risk.
Transthyretin Levels and Nutritional Status
Serum transthyretin, also known as thyroxine-binding prealbumin or prealbumin, has been proposed as an early indicator of nutritional status in hemodialysis patients (4, 6, 13, 14) .
Transthyretin, with a molecular weight of 54,000, is synthesized primarily in the liver and circulates as a stable and symmetrical tetramer composed of four tryptophan rich identical subunits of 127 amino acids each (15, 16) . Transthyretin serves as a transport protein for thyroxine (T4) and a carrier protein for retinol binding protein and therefore vitamin A.
Transthyretin levels in serum increase or decrease in relation to the adequacy of protein or energy intake. Transthyretin decreases rapidly in response to lowered energy or protein intake, even when protein intake is inadequate for a little as three days (15) .
Transthyretin may have advantages over the use of either albumin or transferrin as a short term marker of nutritional adequacy. Transthyretin has a short half life of two days, high tryptophan content, high proportion of essential to nonessential amino acids and small pool size.
It is therefore thought to be a better indicator of visceral protein status and positive nitrogen balance than albumin or transferrin (17) . Concentrations of transthyretin also are not significantly influenced by fluctuations in hydration status which is of clinical significance for hemodialysis patients (15).
Transthyretin Levels in Chronic Renal Failure
Elevated levels of transthyretin have been observed in patients with chronic renal failure (18).
Previously it was thought that the elevated transthyretin levels seen in hemodialysis versus healthy controls discounted its use as a nutritional marker in this population. Cano Goldwasser et a. (6) concluded that transthyretin was actually a stronger independent correlate of mortality risk than albumin concentration. Transthyretin concentration may be more reflective of a distinct aspect of mortality risk than albumin, or albumin concentration may be more influenced by factors unrelated to mortality risk. The increased predictive power was also attributed to the shorter half-life of serum transthyretin, permitting rapid changes in its concentration in response to under nutrition or catabolism. Sreedhara et al. (22) found that there was a higher relative risk of death in hemodialysis patients with a serum transthyretin <30 mg/dl.
A single measurement of transthyretin was found to predict patient survival for up to five years.
Jacob et al. (20) found that transthyretin levels of 0.30 g/liter were fairly sensitive in identifying wasted patients as well as those with a history of recent infection, yet IGF-1 had a higher predictive value. Jacob et al (20) also found that patients with a history of infection in the prior six months had lower intakes of protein and calories as well as lower serum concentrations of transthyretin and IGF-1 when compared with the infection-free patients.
These findings support that a low serum transthyretin level in hemodialysis patients is correlated with increased morbidity and mortality, lower protein catabolic rate and is a valid marker of visceral protein status if altered physiological ranges are taken into account.
METHODOLOGY

Study Design
This was a prospective, cohort, correlation, nonintervention study utilizing convenience sampling. The study was approved by the Florida International University Institutional Review Board prior to implementation.
Subjects and Setting
Patients were selected from a population of seventy seven patients receiving hemodialysis treatments at Complete Dialysis Care, Inc., a free standing outpatient dialysis clinic in Coral Those who developed infection within the six month study period were excluded from the study.
Forty three patients completed the six month study period. Four patients discontinued due to infection, one due to noncompliance with treatments, one expired, one underwent kidney transplantation and one transferred to another facility.
Demographic and Clinical Data Collection
Demographic data included age, gender and race. Clinical data included:
(1) etiology of end stage renal disease obtained from the HCFA 2728 form in the patients' chart, . (4,10) .
Calculations were performed using the Statistical Package for the Social Sciences Version 4.1 software. The mean and standard deviations of study parameters of the subjects for the six month study period are given in Table 3 . The distribution of the mean transthyretin level over six months is illustrated in Figure 1 . The overall mean transthyretin level for all subjects in six months was 32.4-6.8 mg/dl. This is above the acceptable level in the hemodialysis population of 30 mg/dl. Sixty-four percent of the subjects had a mean transthyretin level above 30 mg/dl and thirty-six percent had mean levels less than 30 mg/dl for the six month study period ( Figure   1 ).
RESULTS
Demographic data is included in
Pearson correlation coefficients for the relationship of transthyretin with other nutrition parameters are listed in Table 4 . There was a statistically significant positive correlation between serum transthyretin and serum albumin (r= 0.524, p= 0.000), serum creatinine (r=0.464, p= 0.000) and loss of dry body weight (r= 0.339, p= 0.032). Categoucal data analysis is listed in M sa_ _ ,, . . _,.,,._. ., .. ,.,._.. : h ems-4 S ..... n.;ct e sF.
No statistically significant correlations were found between transthyretin <30 mg/dl and serum cholesterol <150 mg/dl or KT/V<1.2. A comparison of transthyretin levels (Student's t-test) in diabetics versus non-diabetics is shown in Figure 3 . Transthyretin levels were higher in non-diabetics than diabetics for all six months, yet this was only statistically significant (p< 0.05) in two out of the six months. A comparison of other nutrition parameters between diabetics and non-diabetics is shown in Table   6 . Mean creatinine levels (p= 0.02) were significantly lower in diabetics versus non-diabetics and BMI was significantly higher in diabetics (p= 0.034). Mean predialysis BUN and nPCR were lower in diabetics, although this was not statistically significant. Females (p= 0.018) had significantly higher BMI values than males. Mean creatinine levels (p<.001), BMI (p=.018) and body weights (p=.002) were significantly lower in whites than blacks (Students t-test). Mean creatinine levels were also found to be significantly lower in the nine patients who urinated >240 cc in 24 hours (p<.001). There was no significant difference in creatinine levels or transthyretin levels between men and women. 
Figure
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DISCUSSION
This study confirms the usefulness of transthyretin as a marker of nutritional adequacy in hemodialysis patients. The strong correlation of serum transthyretin with other nutrition assessment parameters, serum albumin and creatinine, is in agreement with previous studies of transthyretin by other investigators (4) (5) (6) 22) . The correlation of serum transthyretin with serum creatinine and albumin also supports its significance as a prognostic indicator. Creatinine, which reflects lean body mass, and serum albumin, which reflects visceral protein stores, have both been found to be inversely correlated with mortality in the hemodialysis population (2) . A single measurement of transthyretin less than 30 mg/dl has been found to be an independent predictor of mortality in the hemodialysis population (4) (5) (6) 22) . In hemodialysis patients nPCR values between 1.0 -1.4 gm/kg/day are desirable to maintain lean body mass (1) . The National Cooperative Dialysis Study found that an nPCR >1 gm/kg/day and a BUN >50 mg/dl were associated with lower morbidity (23) . Based on these findings, serum transthyretin may not replace nPCR as a short term indicator of nutritional adequacy, as it may miss patients with nPCR values between 0.8-1.0 gm/kg/day, yet it provides an additional marker for the need for nutrition intervention.
The hypothesis that low levels of serum transthyretin would correlate with low predialysis
The hypothesis that serum transthyretin levels <30 mg/dl would be indicative of inadequate energy intake as evidenced by loss of dry weight was accepted. The correlation between serum transthyretin and loss of dry body weight supports that serum transthyretin may be a marker of inadequate energy intake in patients who are receiving hemodialysis treatments. These findings are in agreement with Vehe et al. (21) where transthyretin correlated significantly with cumulative intakes of both protein and energy, in chronic renal failure patients receiving nutrition support. Transthyretin has been found to correlate with other markers of body mass such as the midarm muscle circumference (4, 13, 20) and triceps skinfold thickness (4, 20) .
A correlation was not found between inadequate dialysis and low transthyretin. This may have been due to an adequate three month mean KTN of 1.47 0.28 and that only two patients (4%) had a three month mean KTN of less than 1.2. Clearly there were not enough patients receiving inadequate dialysis to identify a statistically significant finding. It is recognized that the results involving KTN and nPCR are also limited by the use of single-pool kinetic modeling.
Since transthyretin has a much shorter half life than albumin, we sought to evaluate whether transthyretin levels would rise or fall prior to changes in albumin levels. The hypothesis that transthyretin levels would increase or decrease prior to changes in albumin levels was rejected as a positive association was found between changes in levels of serum albumin and changes in levels of transthyretin. This may have been due to the monthly interval in which specimens were drawn. Since serum levels were only obtained on a monthly basis, changes in transthyretin levels (half-life 1-2 days) that may have occurred before changes in albumin levels (half-life 21 days) were not detected. The strong correlation between albumin and transthyretin levels and the correlation between changes in monthly transthyretin correlating with changes in albumin levels, could be interpreted as negating the advantages of measuring transthyretin as an additional nutrition indicator. Yet, the finding that thirty five percent of the subjects had six month mean transthyretin levels < 30 mg/dl despite a mean albumin level> 3.5 gmldl justifies the use of transthyretin as a marker for patients requiring nutrition intervention that may not have been identified based on serum albumin levels alone. The early identification of patients with poor nutritional intake, through the measurement of serum transthyretin, would allow for early nutrition intervention thereby preventing a further decline in nutritional status and its associated higher morbidity and mortality. As patients with conditions that may influence transthyretin levels (such as the development of infection) were excluded from the study, the changes in transthyretin that occurred without changes in albumin, may be attributed to changes in nutritional intake of dietary protein or energy rather than an acute phase response.
Caution must be used in interpreting transthyretin levels in subjects who urinate >240 cc per day. These subjects were found to have significantly lower transthyretin levels. Subjects who urinated >240 cc per day also had significantly lower creatinine levels, yet no significant difference in serum albumin levels. A statistically significant inverse correlation was not found between total milligrams of urinary protein excreted per day and serum transthyretin levels. Figure 3 ). Diabetics also had lower serum creatinine levels despite significantly higher body mass indexes. This may have been due to an excess of adiposity with a decrease in lean body mass in the diabetics, although body composition measurements were not performed to confirm this. As the presence of diabetes and the presence of low serum transthyretin are both independent predictors of mortality (5, 22) , diabetic subjects who have low serum transthyretin levels represent a group who may benefit from prompt intervention to improve nutritional status.
The above findings are limited by the use of a convenient sample, a limited sample size and a short study period (6 months) , assumption that single pool urea kinetic modeling accurately determines KTV and nPCR, and accuracy of the 24 hour urine collection by the subject. Despite these limitations, the findings support that despite the elevated levels of serum transthyretin in chronic renal failure, serum transthyretin is a useful nutrition assessment parameter after adjustment for altered physiological range.
SUMMARY, CONCLUSIONS, RECOMMENDATIONS
Measuring serial serum transthyretin levels in hemodialysis patients is a reliable method for identifying patients at nutritional risk, as well as patients at higher morbidity and mortality risk. 
RESEARCILRURPSENDURALQN
The research project entitled "Serum transthyretin (prealbumin) in hemodialysis patients: relationship to nutritional status and protein catabolic rate" is to be conducted by Annmarie Duggan R.D., L.D. and Fatma G. Huffman Ph.D., R.D. as Principal Investigators from Florida International University. This research will last approximately 3 months starting Summer 1996 and there will be approximately 70 participants in the total sample.
The purpose of this research is to determine if serum transthyretin is an early marker of adequacy of nutritional status and if there isa correlation between low levels of this protein and a low protein catabolic rate.
2.PROCEDUlRES
You will continue to have your usual monthly lab work drawn. Your albumin, transthyretin, cholesterol and blood urea nitrogen levels will be recorded as study data. For three consecutive months you will also have a pre dialysis blood urea nitrogen and a transthyretin level drawn on the Friday after your monthly bloodwork. During the entire three month study period, only 10 milliliters of additional blood will be drawn. You will be asked to collect a 24 hour urine specimen if you urinate more than 240 cc (8 ounces) per day.
3.RISKS OR DISCOMFORTS
There are no known risks or discomforts involved in your participation in this research study.
BENEFITS 10OU
Although it may not be a directly benefit you to participate, this study will contribute knowledge about adequate nutritional assessment for hemodialysis patients and could result in the early identification for your need for nutrition intervention. You will continue to receive your routine monthly nutrition counseling as usual. There will be no cost to you for taking part in this study.
PAYMENT FOTAKING PART IN _RESEARCHSTUDY
You will not be paid for taking part in this research study.
7.CONFIDENTI ALIY
All information which refers to, or can be identified with you, will remain confidential to the extent permitted by law. No information will be revealed about you or your part in this study, without your permission or the permission of your legally authorized representative, except that which may be necessary for the Research Committee to satisfy their legal responsibility for review of the project.
. C_ AI E_ Financial compensation for research-related injury of loss of wages is not available; however, necessary emergency medical care will be provided without cost, if not covered by a third parly payer.
WHQCO-NAC LORASWERS
If you desire further information about this research contact Fatma Huffman Ph.D. at 305-348-2878 at Florida International University or Annmarie Duggan, R.D. at 954-345-2446.
PARTCIPATION&-V-OLUNTARY
Your participation in this study is voluntary. If you wish, you may choose not to take part in this study. You may withdraw your consent and discontinue participation in this research project at any time without any negative consequences. . JEIVOELESIU OYDRACIO El estudio titulado "Suero transthyretina en pacientos de dialisisrelacionado con pa nutricion y el indice de catabolismo de proteina" sera conducido por Annmarie Duggan R.D., LD. y Fatma G. Huffman Ph.D., RD. coma principiantes investigadoras de la Universidad Internacional de Ia Florida. Este estudio durara aproximadamente tres meses comensando en 1996 y habran aproximadamente 70 participantes en el estudlo. El objetivo de este estudio es para determinar si transthyretina es un indicador prematuro de una atimentacion adecuada y si hay una corretacion el estatus nutricionat entr niveles vajos de esta proteina y el indice catabolismo de proteina.
I HAVE READ, UNDERSTOOD, AND RECEIVED
2.PROCEDMIENTOS
A usted le van hacer sus trabajos de laboratoric mensuatmente como siempre. Su atbumina, transthyretina, catesterot y urea sanguinea seran anotados como datos del estudio. Par 3 meses consecutivos, le tomarar, su nivel de urea sanguinea para calcular el indice de (un indicador de su proteina ingerida)p Sera requerido que usted obetnga de orina cada 24 hrs. En el caso de que pueda orinar mas de 8 onza at dia.
RIESGOS EANCOMODJDADES
No hay riesgos conocidos ni incomodidades envolucrados con su participacion en esta investigacion.
BENEFICIOS PARA USTED
Aunque su participacion no Io beneficie directamente, esta investigacion sera muy constructiva para poder determinar una mejor evaluacion alimenticia y al mismo tiempo padremos identificar si usted necisita alteraciones en su dieta.
Usted tendra sus spsiones consultorias con la dietista mensualmente como se acostumbra.
Iniciales del paciente _
31
No habra costo alguno por su participacion en este estudlo. Su copaboracion en este projecto, tendra un valor muy importante par la el futuro de todos los pacientes que se encuentrar en dialisis.
RECOMPESAROR PAICIPACO El -ES TESTUDO
No habra recompensa monetaria par su participacion en el estudia.
7 CONEIDENCIA tDAD Toda Ia informacion que se refiera a usted a que puedo ser identificada con usted semantendra confidencial segun permeitne las leyes de la fha. Ninguna inforracion sobre usted o sobre su paricipacion sera revelada sin su permiso a el permiso de su abogado solamente sera la dibulgada informacion que sera utilizada par el comite de Investigacion. Toda Ia informacion sera utilizada dentro de tfos los ambitos legales que pemite Ia ley. 
ESEAS
